See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Venture Capital

REVA Medical, Inc. Raises $42 Million in Private Financing

    SAN DIEGO, Dec. 10 /PRNewswire/ -- REVA Medical, Inc., a company
 developing novel bioresorbable stents to treat arterial disease, today
 announced it has raised $42 million in a private financing led by Cerberus
 Capital Management and Brookside Capital, an affiliate of Bain Capital.
 Also participating in the round are Pequot Capital Management, Inc. and
 Medtronic, along with previous investors Domain Partners and Group Outcome
 LLC. The proceeds will be used to continue the development and clinical
 testing of REVA's bioresorbable stent products.
 
     "REVA continues to develop what we believe to be the most promising
 approach for a stent that performs its important function and then safely
 dissolves," said Bob Stockman, REVA Chairman. "Today, we match a
 world-class medical investor group with a world-class program. These new
 funds should provide adequate capital to fund the Company into clinical
 development that will help position REVA very strongly for the future."
 
     Boston Scientific Corporation (NYSE:   BSX) maintains its equity position
 in the Company and will hold an exclusive option for global distribution
 for the Company's resorbable coronary and peripheral stent products.
 
     REVA Medical, Inc. is developing interventional medical devices that
 leverage the Company's novel stent designs and biomaterial technologies to
 improve the treatment of vascular disease. For more information, please
 visit http://www.teamreva.com.
 
 
 

SOURCE REVA Medical, Inc.